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  One of the least studied topics in the field of obstetrics is liver disease during pregnancy, which creates a chal-
lenge for both gynecologists and hepatologists. Approximately 3% of pregnant women are affected by some 
form of liver disease during pregnancy. Some of these conditions can be fatal for both the mother and child. In 
addition, 3 types of liver disease need to be differentiated during pregnancy. One type is liver disease direct-
ly related to pregnancy, which can occur at a specific time during pregnancy. Another type is liver disease not 
related to pregnancy, which can occur at any time, such as viral- or drug-induced hepatitis. Furthermore, preg-
nancy can occur in women with pre-existing liver disease. It is essential that the clinicians are familiar with 
this disorder so they can respond promptly and appropriately in all of these situations, especially when emer-
gency delivery is needed and must not be postponed.
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Background
Liver disease during pregnancy is relatively poorly studied and 
poses a challenge for the consulting gynecologist and hepa-
tologist. Nearly 3% of pregnancies are complicated by some 
form of liver disease, and severe pregnancy-related liver dis-
eases can have fatal consequences for both mother and child. 
Diagnostic and therapeutic decisions must consider the im-
plications for both the mother and child, and rapid diagno-
sis is indispensable for severe cases because the decision of 
immediate delivery is important for maternal and fetal out-
come. Pregnant women undergo some physiological chang-
es that can mimic liver disease; therefore, they must be con-
sidered in the diagnostic approach to women with suspected 
liver disease [1–6]. Pregnancy is associated with a hyperdy-
namic circulatory status, as maternal cardiac output and heart 
rate increase during pregnancy. On the other hand, the blood 
supply to the liver remains unchanged [2–6]. Spider angioma 
and palmar erythema, which are typical clinical markers of liv-
er disease, are commonly seen during pregnancy as a conse-
quence of the hyperestrogenic state. These physical chang-
es usually disappear after delivery. Gall bladder motility is 
decreased, increasing the incidence of cholelithiasis in preg-
nant women [3–6]. Biochemical and hematological tests dur-
ing normal pregnancy show decreased albumin in all trimes-
ters due to hemodilution, and the decline in albumin levels 
becomes more pronounced as pregnancy advances. Alkaline 
phosphatase (ALP) is increased in the third trimester, but it is 
of placental origin due to fetal bone development. Alpha fe-
toprotein (AFP) levels also increase because it is produced by 
the fetal liver [1–7]. In contrast, other liver biochemical tests, 
such as total bile acids concentration, serum alanine transam-
inase (ALT), aspartate transaminase (AST), gamma-glutamyl 
transpeptidase (GGT), and bilirubin, remain within the nor-
mal range during normal pregnancy. However, because of he-
modilution, their ranges can change, with a reduction in the 
upper limit [1,3]. Pregnancy is a pro-coagulant state in which 
clotting factors (I, II, V, VII, X, and XII) and fibrinogen are in-
creased, whereas the ranges for prothrombin time (PT) and 
activated partial thromboplastin (APT) time are within normal 
values [1,3]. Therefore, elevations in transaminases, bilirubin, 
fasting total bile acids, or the PT above the normal range dur-
ing pregnancy are abnormal and indicate a pathological state 
that requires prompt evaluation [1].
In pregnant women with suspected liver disease we should dis-
tinguish the 2 main categories of liver disease: non-pregnan-
cy-related liver diseases and the few diseases directly related 
to pregnancy [1,2]. Pregnancy-related liver disorders, in their 
occurrence, exhibit trimester-specific characteristics, where-
as non-pregnancy-related liver diseases can occur at any time 
[3]. The timing of the occurrence of clinical manifestations and 
abnormal liver tests is critical in determining diagnosis and 
treatment strategies. For example, hyperemesis gravidarum 
(HG) is a pregnancy-related liver disorder of early pregnan-
cy, whereas intrahepatic cholestasis of pregnancy (ICP), pre-
eclampsia with liver involvement including hemolysis, elevat-
ed liver enzymes, and low platelets (HELLP) syndrome, and 
acute fatty liver of pregnancy (AFLP) are conditions affecting 
the liver in late pregnancy [1,3,7]. According to the literature, 
a mortality rate of 0 to 25% has been reported among moth-
ers with pregnancy-related liver diseases. The main factors 
determining the maternal prognosis are the cause of the liver 
disease, the degree of impaired synthetic, metabolic, and ex-
cretory liver function, and timing of delivery (i.e., the delay in 
delivery in HELLP or AFLP) [8–10]. Liver disorders that are co-
incidental with pregnancy can be classified as those that are 
present de novo during pregnancy, or pregnancy can occur 
in women with pre-existing chronic liver disease (CLD) [1,3]. 
Due to limited space, this group of diseases will not be dis-
cussed in this review.
Recent investigations and subsequent advances in medical 
treatment have resulted in improved, but still unsatisfactory, 
maternal and fetal outcomes. Here, we review recent advanc-
es in understanding the etiologies, clinical courses, and man-
agement of liver disease in pregnancy, especially liver diseas-
es unique to pregnancy.
Pregnancy-Related Liver Disorders
Hyperemesis gravidarum
HG is defined as nausea and intractable vomiting that results in 
dehydration, ketosis, and weight loss >5% of body weight [1,11]. 
HG complicates approximately 0.3–2.0% of pregnancies dur-
ing the first trimester. Symptoms usually start before the 9th 
week of gestation and disappear by the 20th week of gesta-
tion [1,2,11]. HG is not a true liver disease, but it is associat-
ed with abnormal liver test results in approximately half of 
cases [1,3,7]. Multiple gestations, increased body mass index 
(BMI), pre-existing diabetes, psychiatric illness, and HG in a 
previous pregnancy have been shown to be risk factors for 
HG development [7].
Clinical signs lead to dehydration and increased renal values, 
electrolyte abnormalities, metabolic alkalosis, and erythrocy-
tosis [1,2,7,12]. Abnormal liver test results are observed in ap-
proximately half of all pregnant women [2,13–15]. Elevations 
in serum aminotransferases usually go up to 200 U/L and this 
is the most common abnormal liver test result. Other biochem-
ical abnormalities, such as increased serum amylase and li-
pase values, may also be seen [1,3,7]. In addition to laboratory 
tests, an abdominal ultrasound must demonstrate normal liv-
er parenchyma without biliary obstruction, and an obstetrical 
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ultrasound can exclude hydatidiform mole and multiple gesta-
tion [1–3,7,12]. In pregnant women presenting with abnormal 
liver enzymes with or without HG in the first trimester, oth-
er causes of abnormal liver enzymes must be ruled out [1,3].
The management of HG is supportive and includes intrave-
nous fluid replacement, correction of electrolyte abnormali-
ties, use of antiemetics, possible parenteral nutrition, and vi-
tamin supplementation [1,2,7,14,16].
Intrahepatic cholestasis of pregnancy
ICP is the most common cause of cholestasis during pregnan-
cy and the most common pregnancy-related liver disease. ICP 
is a form of liver disease characterized by a reversible cho-
lestatic condition that usually occurs during the late second 
and third trimester, although rarely it is present as early as 7 
weeks of gestation. ICP has rapid postnatal resolution, with 
signs and symptoms usually disappearing spontaneously with-
in 6 weeks of delivery. ICP recurs in more than half of sub-
sequent pregnancies [1–3,7,17–20]. The incidence of ICP var-
ies widely, with geographic variations in the rate of disease. 
The incidence rate in Europe has been reported to range from 
0.5% to 1.8% of pregnancies. The highest peak of incidence 
was reported in South American countries (up to 28%) and in 
Scandinavia. Interestingly, ICP is more common during cold-
er months in Scandinavian and South American countries, for 
unknown reasons [1,7,17–21]. The risk factors reported to be 
associated with increased incidence of ICP are maternal age 
>35 years, multiparity, history of oral contraceptive use, his-
tory of fertility treatment in women, and history of ICP during 
previous pregnancies [1,5,20,22,23].
Pathophysiologically, in ICP there is an abnormal biliary trans-
port across the canalicular membrane, with multifactorial eti-
ology [3,20,24–28]. Genetic, hormonal, and environmental 
factors have been reported to play a role in ICP etiopatho-
genesis [3,5,20]. ICP appears late in pregnancy, when serum 
concentrations of estrogen reach their peak; it has a higher 
incidence in twin pregnancies, which have higher estrogen 
levels, and resolves after delivery, when sex hormone levels 
fall [2,3,5,20,28–30]. Another interesting observation in the 
context of ICP is its seasonal variability in some countries. 
Environmental factors may induce ICP in genetically suscep-
tible patients. According to epidemiological data, ICP is more 
common in the winter. Seasonal variations in ICP have been 
assumed to be associated with dietary factors related to low 
maternal levels of selenium and zinc and high levels of cop-
per [20,28,30].
The main symptom of ICP is pruritus, which typically pre-
dominates on the palms and soles of the feet and wors-
ens at night [1,20]. Pruritus often develops after 25 weeks of 
gestation, with 80% of cases occurring after the 30th week [3]. 
Other symptoms of ICP can include steatorrhea, malabsorp-
tion of fat-soluble vitamins, and weight loss due to cholesta-
sis [5]. Jaundice has an incidence of 14–25% and may develop 
1 to 4 weeks after the onset of pruritus, with dark urine and 
pale feces in some women [20,31]. The most important bio-
chemical test in the context of ICP is total bile acids concen-
tration, which can be the first, and sometimes only, laboratory 
abnormality [1,20]. Serum bile acid values may fluctuate and 
increase with advancing pregnancy; therefore, it is advisable 
to check it weekly in women with ICP [1]. The levels of serum 
bile acids also have a prognostic value. According to earlier 
reports, there is an association between the maternal serum 
bile acid concentration and the risk of undesired pregnan-
cy outcome (spontaneous and iatrogenic preterm labor, still-
birth, and admission to the neonatal unit) [1,31,32]. Recently, 
Geenes et al. [32] prospectively analyzed the relationship be-
tween the risk of adverse perinatal outcomes, including still-
birth, and non-fasting serum bile acid levels in women with 
ICP. The most important finding of the study was that the risk 
of perinatal complications is increased in women with non-
fasting serum bile acid levels ³40 μmol/L [32,33]. Therefore, 
>40 µmol serum bile acids in severe ICP is currently considered 
to be associated with adverse pregnancy outcomes [1,7,32]. 
Aminotransferases are usually increased by 2 to 10 times, but 
may be elevated by up to 20 times; the serum GGT levels are 
normal or moderately elevated in less than one-third of cases, 
whereas bilirubin levels rarely exceed 100 μmol/L [3,5,20,33]. 
ALP is also elevated, but this increase is non-specific due to 
placental production of the enzyme [5]. PT is often normal, but 
may be prolonged due to vitamin K malabsorption [3,5]. On 
abdominal ultrasound, there are no abnormal findings for the 
liver parenchyma and no dilatation of biliary ducts. Liver biopsy 
is rarely necessary and is not routinely performed. When per-
formed, histopathology is characterized by intrahepatic cho-
lestasis without parenchymal inflammation [3,5,20]. However, 
in some cases of uncertain diagnosis, considering liver biop-
sy is advisable, such as in women with jaundice but without 
pruritus, symptoms beginning before 20 weeks of gestation, 
and persistent abnormal laboratory findings beyond 8 weeks 
after delivery [20,34]. In patients with suspected ICP, other 
hepatobiliary diseases must be excluded [20].
The goals of ICP treatment are to reduce maternal symptoms, 
improve laboratory test results, and improve fetal outcome. 
The first-line therapy for ICP is ursodeoxycholic acid (UDCA) 
at a dose of 500 mg twice a day or 15 mg/kg per day [20,35]. 
UDCA is safe in the third trimester because no maternal or 
fetal adverse effects have been reported regarding the use of 
this medication in ICP [20]. Other medications, such as cho-
lestyramine and S-adenosyl-methionine, have not had satis-
factory results [5,20,36,37]. In women who do not respond to 
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UDCA, combining rifampicin with UDCA improves their symp-
toms and laboratory abnormalities [38].
ICP has a high recurrence rate (40–70%) in subsequent preg-
nancies [1]. Generally, ICP is a benign condition for the mother, 
and pruritus often disappears in the first days following deliv-
ery, with the normalization of laboratory tests (i.e., serum bile 
acid concentrations and other liver tests). Liver tests and bile 
acid concentrations controls are recommended 6 to 8 weeks 
after delivery. If a woman has biochemical liver impairment 
for more than 3 months postpartum, she should undergo ad-
ditional clinical investigations to exclude other or co-existing 
liver diseases [1]. According to recent data, ICP is associated 
with an increased risk of developing other hepatobiliary dis-
eases, such as hepatitis C, cirrhosis, and gallstones. In addi-
tion, patients with underlying chronic liver disease (e.g., hep-
atitis C or chronic hepatitis of different etiologies) have an 
increased risk of developing ICP [5,21]. The cause of this ef-
fect is not known, but in light of observations of a strong pos-
itive association between ICP and hepatitis C both before and 
after ICP diagnosis, authors advocate testing for hepatitis C in 
women with ICP [1,5,21].
In contrast to the favorable prognosis for women with ICP, it 
may be associated with poor perinatal outcome and increased 
risk of preterm labor, fetal distress, and sudden intrauterine 
fetal death, which is the most concerning issue. As mentioned 
above, severe ICP with adverse pregnancy outcome is associ-
ated with serum bile acids >40 µmol/L [1,7,39].
In summary, the main clinical symptom of ICP is pruritus, which 
often develops after 25 weeks of gestation, with most cases 
occurring after 30 weeks [3]. Serum total bile acids concen-
tration is the most useful biochemical test, as it may be the 
first and possibly only test result that is abnormal, but the val-
ues may fluctuate with advancing pregnancy, making weekly 
checks advisable in women with ICP [1]. Generally, ICP is a be-
nign condition for the mother, but it may be associated with 
poor perinatal outcome and increased risk of preterm labor, 
fetal distress, and sudden intrauterine fetal death. The first-
line therapy for ICP is 500 mg UDCA twice a day or 15 mg/kg 
per day [20].
Acute fatty liver of pregnancy
AFLP is a microvesicular fatty infiltration of hepatocytes that is 
also known as acute yellow atrophy or acute fatty metamor-
phosis [1,3]. AFLP is a medical and obstetric emergency be-
cause it can be fatal for both the mother and child in the ab-
sence of early recognition and appropriate management [1,7]. 
AFLP is a rare condition, usually occurring in the third trimes-
ter, with an approximate incidence of 1: 7000 to 1: 16 000 
pregnancies. Rarely, AFLP can occur as early as 22 weeks of 
gestation [7,40,41]. Risk factors include multigravidas, pre-
eclampsia, multiple gestation, and male fetus and it is possi-
bly more common in women who are underweight [1,7,41].
The pathogenesis of AFLP is not fully understood, but inves-
tigations over the past few years suggest that it may result 
from mitochondrial dysfunction in most cases [5,41]. Some 
cases of AFLP have a defect in mitochondrial fatty acid oxida-
tion in both the mother and fetus. Two enzymes are involved 
in mitochondrial fatty acid oxidation, and mutations in these 
enzymes are thought to be closely associated with AFLP: mi-
tochondrial trifunctional protein and its alpha subunit long-
chain 3-hydroxyacyl-CoA-dehydrogenase (LCHAD) [3,42]. Earlier 
reports demonstrated that mothers of neonates with LCHAD 
deficiency have a 79% chance of developing AFLP or HELLP 
syndrome [1,3,41,43,44]. AFLP usually occurs in the third tri-
mester, rarely before the 30th gestational week, but up to 20% 
of cases present postnatally [1,45]. Clinical presentation is 
variable and includes non-specific symptoms such as nausea, 
vomiting, abdominal pain, headache, and malaise. The clini-
cal course can rapidly progress to acute liver failure and its 
complications, such as encephalopathy, jaundice, and coagu-
lopathy [1,3,7,41,46].
Laboratory tests can show abnormal liver values, including el-
evated aminotransferase levels (from mild elevation to 1000 
IU/L, but usually 300–500 IU/mL) and hyperbilirubinemia (fre-
quently >5 mg/dL). Often, leukocytosis, normochromic anemia, 
and thrombocytopenia are present, as well as hypoalbumin-
emia, elevated uric acid, renal dysfunction, metabolic acidosis, 
hyperammonemia, and biochemical pancreatitis. Ketonuria and 
proteinuria can be present. Hypoglycemia is characteristic and 
predicts a poor prognosis. In severe cases, prolonged PT and 
reduced fibrinogen levels may be found, whereas disseminated 
intravascular coagulation (DIK) is seen in approximately 10% of 
patients with AFLP. A number of women with AFLP have com-
plications, such as ascites, pleural effusions, and acute pan-
creatitis, or respiratory and renal failure. Infections are com-
mon, as well as vaginal bleeding or bleeding from Caesarean 
section wounds because women with AFLP are extremely sus-
ceptible to developing coagulopathies due to impaired syn-
thetic liver function and/or DIC [1–3,7,41,47].
The diagnosis of AFLP is based on clinical and laboratory find-
ings. Microvesicular steatosis on liver biopsy is the criterion 
standard, but is rarely necessary [7,41]. Imaging may be use-
ful to exclude other disorders (e.g., hepatic infarct or hema-
toma). On abdominal ultrasonography or computed tomogra-
phy (CT) there are signs of fat infiltration, and current imaging 
methods have limited utility in the diagnosis of AFLP. However, 
further research is needed to determine non-invasive imag-
ing methods that will be acceptable as a part of the stan-
dard workup for AFLP in the future [1,5,41]. Fifteen years ago, 
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Ch’ng et al. [48] published a study in which they proposed di-
agnostic criteria, known as the Swansea criteria, for the diag-
nosis of AFLP (Table 1). According to these criteria, presence 
of 6 or more of these features in the absence of other etiol-
ogies is suggestive of AFLP [48]. The Swansea criteria have a 
sensitivity of 100% and specificity of 57%, with positive and 
negative predictive values of 85% and 100%, respectively, for 
the diagnosis of AFLP [5,49,50].
The main differential diagnosis is HELLP syndrome due to the 
great overlap between AFLP and HELLP syndrome. Thus, dis-
tinguishing between these 2 disorders is often very difficult, 
potentially delaying diagnosis [7,17,41]. Early recognition of 
the disease and delivery of the fetus regardless of gestational 
age are the keys to successful management, followed by ma-
ternal care, which is mainly supportive. There are no reports 
in the literature of recovery before the delivery of the child. 
The life-threatening condition associated with AFLP is acute 
liver failure. Thus, aggressive maternal stabilization in an in-
tensive care setting is necessary, with correction of coagu-
lation, hypoglycemia, and other abnormalities [1–3,5,41]. In 
some non-randomized reports, the use of plasma exchange 
(PE), as well as PE in combination with continuous renal re-
placement therapy (CRRT), following delivery was associated 
with improved clinical outcomes, including reduced maternal 
mortality [51–53]. Liver transplantation (LT) has been report-
ed sporadically as a last-chance measure [1,54]. In a retro-
spective analysis, Westbrook et al. [54] evaluated 54 cases of 
pregnancy-related liver disease; 18 had AFLP and 32 had hy-
pertension/eclampsia-related disease. The survival rates were 
43/48 if not listed for LT and 4/6 if listed. Of the 4 transplant-
ed patients, 3 survived. The study shows the overall favorable 
prognosis in pregnancy-related liver failure, but also shows 
that elevated lactate levels in the presence of encephalopa-
thy best identify women at greater risk of morbidity or death 
or for LT, whereas the King’s College criteria were not effec-
tive in predicting outcome [54].
Most women recover during the first month after delivery, but 
cholestasis may persist longer. Histological changes resolve 
after delivery, but may persist for up to 5 weeks. If there are 
no signs of pre-existing CLD, recovery is complete. All women 
and their children should be screened (by molecular testing) 
for LCHAD mutations, mainly for the most common G1528C 
mutation [1–3,5,41,55].
In summary, AFLP is a medical and obstetric emergency be-
cause it can be fatal for both the mother and child. AFLP is a 
rare disease and usually occurs in the third trimester [7,40]. 
Diagnosis is usually reached according to clinical and lab-
oratory findings, exclusion of other liver diseases, and the 
Swansea diagnostic criteria [1,48]. The main differential diag-
nosis is HELLP syndrome, but signs of liver failure with coag-
ulopathy, hypoglycemia, and encephalopathy, as well as renal 
impairment, are more common in women with AFLP [3]. Early 
recognition of the disease and prompt delivery regardless of 
gestational age are key to successful management, in addi-
tion to aggressive maternal supportive care, mainly in the in-
tensive care unit [1–3,5,41]. In the absence of signs of pre-ex-
isting CLD, most women recover completely during the first 
month after delivery. However, more research is needed to un-
derstand the epidemiology of AFLP and evaluate the long-term 
maternal outcome [41].
Preeclampsia, eclampsia, and HELLP syndrome
According to the international society that studies hyperten-
sion during pregnancy, preeclampsia is a multisystem disorder 
defined by de novo hypertension after the 20th week of preg-
nancy with blood pressure (BP) ³140/90 mmHg and protein-
uria of >300 mg/day in association with other organ dysfunc-
tion of the mother, such as renal impairment, liver involvement, 
neurological or hematological complications, and uteroplacen-
tal dysfunction, as well as fetal growth restriction [1,56]. The 
main feature that distinguishes eclampsia from preeclampsia 
is the presence of seizures [2].
Nausea/vomiting Leukocytosis (>11×106/L)
Abdominal pain (mainly epigastric) Elevation in serum ammonia (>47 mmol/L)
Polydipsia/polyuria Elevated transaminases (>42 IU/L)
Encephalopathy Ascites or bright liver on ultrasound
Elevated bilirubin (>14 mmol/L) Renal failure (creatinine >150 mmol/L)
Hypoglycemia (<4 mmol/L) Coagulopathy (PT >14 s or APTT >34 s)
Elevated uric acid (>340 mmol/L) Microvesicular steatosis on biopsy
Table 1. Proposed Swansea diagnostic criteria for the diagnosis of acute fatty liver of pregnancy [49].
PT – prothrombin time; APTT – activated partial thromboplastin time.
4084
Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System]  
[ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica]  
[Chemical Abstracts/CAS]
Mikolasevic I. et al.: 
Liver disease during pregnancy…
© Med Sci Monit, 2018; 24: 4080-4090
REVIEW ARTICLES
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
HELLP syndrome is a variant of severe preeclampsia that oc-
curs in up to 12% of patients with preeclampsia, but can also 
occur in normotensive patients [5,57]. Risk factors for HELLP 
are advanced maternal age and multiparity [7]. The syndrome 
is characterized by the presence of hemolysis, elevated liver 
aminotransferases, and low platelet counts [3]. The disorder 
can be diagnosed antepartum (in 70% of women between 
27 and 30 weeks) or postpartum [7]. In the postpartum peri-
od, the HELLP syndrome often develops within the first 48 h, 
usually in patients who had proteinuria and hypertension pri-
or to delivery [58].
Pathophysiologically, it is assumed that some molecules re-
leased from the placental tissue, such as nitric oxide, pros-
taglandins, and endothelin, can induce platelet aggregation, 
endothelial dysfunction, and hypertension. Consequently, en-
dothelial injury and fibrin deposition in blood vessels is re-
sponsible for the development of microangiopathic hemolytic 
anemia (schistocytes and Burr cells on smear), with platelet 
activation and consumption [1,3]. Liver dysfunction is consid-
ered to be secondary to fibrin deposition within the hepat-
ic sinusoids, resulting in sinusoidal obstruction, vasospasm 
of the liver vascular bed, and liver ischemia. This may some-
times lead to large hematomas, capsular tears, and intraper-
itoneal hemorrhage [1,3,59].
The diagnosis of HELLP syndrome is based mainly on clini-
cal features. Women often present with fluctuating colic-like 
pain in the upper abdomen, usually epigastric or in the right 
upper quadrant. In addition, non-specific symptoms such as 
nausea, vomiting, and malaise are often present. Arterial hy-
pertension and proteinuria are noted in most women. Due to 
microangiopathic hemolytic anemia, unconjugated bilirubin 
and LDH are increased, whereas liver enzymes are moderate-
ly elevated (ALT 2–30 fold). Low haptoglobin may be used as 
another parameter for the diagnosis of hemolysis. The pres-
ence of schistocytes or Burr cells on smears reflects the devel-
opment of microangiopathic hemolytic anemia. Furthermore, 
renal impairment is common. In pregnant women, thrombo-
cytopenia (PLTs <150×109/L) can be a consequence of gesta-
tional thrombocytopenia (59%), immune thrombocytopenic 
purpura (11%), preeclampsia (10%), or HELLP syndrome. In 
addition, <100×109 PLTs/L is relatively rare in preeclampsia 
and gestational thrombocytopenia, but is frequent in immune 
thrombocytopenic purpura and obligatory in HELLP syndrome. 
In severe cases, DIK may occur with evidence of elevated fi-
brin degradation products, low fibrinogen, and an increased 
PT [1–3,5,58,60,61]. According to the literature, there are 2 
classifications of HELLP syndrome: the Tennessee (Table 2) 
and Mississippi classifications, which classifies the disorder 
by PLT values (Table 3) [60]. In the Mississippi classification 
system, class 3 HELLP syndrome is considered to be a clinical-
ly significant transition phase of HELLP syndrome, which has 
the ability to progress [58,60].
Abdominal imaging methods, such as ultrasonography, CT, and 
MRI, should be performed in all women with HELLP syndrome 
in order to investigate liver complications, such as liver infarc-
tion, intraparenchymal hemorrhage, subcapsular hematoma, 
and hepatic rupture [1,3,62]. In cases in which liver biopsy was 
performed, histological changes in the liver in HELLP syndrome 
include periportal changes with hemorrhage, sinusoidal fibrin 
deposition, and hepatocyte necrosis [1,63].
As mentioned above, HELLP syndrome and AFLP share simi-
lar presentations. The differential diagnosis among AFLP and 
HELLP syndrome is shown in Table 4 [1,5]. In addition, HELLP 
syndrome must be distinguished from other rare, but life-
threatening, diseases such as thrombotic thrombocytopenic 
purpura and hemolytic uremic syndrome [3,58].
After HELLP develops, the only definitive treatment is deliv-
ery of the fetus and stabilizing the maternal clinical condition. 
Steroids should be given only for fetal lung maturity, but their 
use is unclear and remains controversial [57,58,64,65]. In a re-
cent meta-analysis, Mao et al. [64] investigated the efficacy of 
corticosteroid therapy in patients with HELLP syndrome, report-
ing that treatment with corticosteroids significantly improved 
the PLT count, LDH levels, and ALT levels, but the decrease in 




Table 2. Tennessee HELLP diagnostic criteria [60].













AST or ALT ³40 IU/L
LDH ³600 IU/L
Table 3. Mississippi HELLP diagnostic criteria [60].
HELLP – hemolysis, elevated liver function tests, and low 
platelet counts; AST – aspartate aminotransferase; ALT – alanine 
aminotransferase; LDH – lactate dehydrogenase.
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also associated with a significantly lower blood transfusion rate 
and shorter hospital/intensive care unit stay [64].
After delivery, the mother should continue to be closely mon-
itored. The PLT counts and other laboratory abnormalities of-
ten return to normal levels within 2 weeks of delivery [2]. The 
prognosis of maternal mortality is approximately 1.1%, but 
higher maternal mortality of up to 25% has been reported. 
The rate of maternal mortality in hepatic rupture ranges from 
18% to 86% [58,66–68]. The perinatal mortality rate relat-
ed to HELLP syndrome is between 7.4% and 34% [58,69–71]. 
Complications, such as prematurity or placental insufficiency, 
with or without intrauterine growth restriction and placental 
abruption, are the main causes of neonatal death. Hepatic rup-
ture has a perinatal mortality rate of up to 80% [58,72–75].
In summary, HELLP syndrome is a variant of severe preeclamp-
sia that occurs in up to 12% of patients with preeclampsia, 
and 10–20% of cases are normotensive patients [5,57]. HELLP 
syndrome is defined by the presence of hemolysis, elevated 
liver aminotransferases, and low PLT counts [3]. This disorder 
is primarily diagnosed antepartum (between 27 and 30 weeks 
in 70% of women), but is diagnosed postpartum in approxi-
mately 30% of cases [7]. Diagnosis is based mainly on clini-
cal features and laboratory findings. The differential diagnosis 
among AFLP and HELLP syndrome is the main diagnostic chal-
lenge, but HELLP syndrome must also be distinguished from 
some other rare, but life-threatening diseases, such as throm-
botic thrombocytopenic purpura and hemolytic uremic syn-
drome. Thus, once HELLP develops, the only definitive treat-
ment is delivery of the fetus and stabilization of the maternal 
clinical condition. Laboratory abnormalities often return to nor-
mal levels within 2 weeks of delivery [2,3,58].
Pre-Existing Liver Diseases and Pregnancy
Cirrhosis and portal hypertension
Pregnancy is relatively rare in women with liver cirrhosis. When 
pregnancy occurs, the risk of spontaneous abortion, prematu-
rity, and perinatal death are very high. However, with advance-
ments in the medical field, pregnancy is not contraindicated in 
these women, as previously believed [3,4,7]. The outcome of 
pregnancy is related to the severity of the maternal liver dis-
ease. The model for end-stage liver disease (MELD) has been 
shown to be a good model for predicting the risk of decom-
pensation of maternal liver disease during pregnancy [1]. A 
few years ago, Westbrook et al. [76] showed that a pre-con-
ceptional MELD score ³10 had 83% sensitivity and specificity 
for predicting liver decompensation during pregnancy [1,76].
In pregnant women with cirrhosis, the most common and most 
serious complication is variceal bleeding. Due to worsening 
of portal hypertension (PH) because of increased circulating 
blood volume and direct pressure of the gravid uterus on the 
inferior vena cava, impairing venous return, variceal bleed-
ing occurs mainly during the second trimester and the in the 
second stage of labor [1,3,75–80]. Therefore, active manage-
ment of varices is essential before and during pregnancy [80].
Upper gastrointestinal (GI) bleeding from varices has high 
mortality and morbidity rates in women with pre-existing 
cirrhosis and PH because it is often complicated by liver de-
compensation with worsening synthetic, metabolic, and ex-
cretory function of the liver, manifesting as jaundice, hepatic 
encephalopathy, coagulopathy, and ascites [1,3]. In contrast 
to women with PH due to liver cirrhosis, women with non-cir-
rhotic PH usually have preserved synthetic liver function and 
HELLP AFLP
Prevalence 0.10% 0.01%
Timing of occurrence Late second trimester to early postpartum Third trimester
Clinical findings Abdominal pain, nausea/vomiting, overlap with 
findings in preeclampsia – often hypertension 
and proteinuria
Abdominal pain, nausea/vomiting, hypoglycemia, 
signs of more significant liver disease and possibly 
liver failure, ascites
Laboratory findings Increased ALT, up to 2–30-fold; 
total bilirubin, up to 1.5–10-fold; 
Decreased platelets in all; LDH ³600 IU/mL; 
renal impairment; 
PT may remain normal, normal fibrinogen
Increased ALT, up to 3–15-fold; 
total bilirubin, up to 3–15-fold; 
not necessarily associated with low platelets; 
Leukocytosis, decreased serum glucose 
concentration, renal impairment, decreased 
antithrombin III, prolonged PT, low fibrinogen, DIC
Management Rapid delivery Rapid delivery, plasmapheresis, liver transplantation
Table 4. The differential diagnosis among AFLP and HELLP syndrome [1,5,41].
HELLP – hemolysis, elevated liver function tests, and low platelet counts; AFLP – acute fatty liver of pregnancy; ALT – alanine 
aminotransferase; LDH – lactate dehydrogenase; PT – prothrombin time; DIC – disseminated intravascular coagulation.
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the reproductive system is rarely affected. Although the inci-
dence of variceal upper GI bleeding in these women is simi-
lar to the incidence in women with cirrhosis, the overall prog-
nosis is significantly better [1,77,78]. For women with varices 
that lack “high-risk stigmata”, prophylaxis with beta-blockers 
(propranolol or nadolol) should be initiated [1,7]. In contrast, 
spironolactone should be discontinued [1,3,7,77]. In women 
who did not have an upper GI endoscopy prior to pregnancy 
and those with no varices before pregnancy, upper GI endos-
copy should be performed during the second trimester for the 
reasons mentioned above [1,7].
In women with an episode of an acute variceal bleeding dur-
ing pregnancy, treatment should be focused on the resuscita-
tion and hemodynamic stabilization of the mother, antibiotic 
prophylaxis, and endoscopic therapy. The preferable endo-
scopic method for bleeding esophageal varices is endoscopic 
variceal band ligation [1,3]. Although sclerotherapy is avoid-
ed in most centers due to the risk of injecting sclerotherapeu-
tic chemicals, there have been reports of successful hemosta-
sis with sclerotherapy [1,3,79]. The use of vasopressin is not 
recommended during pregnancy and the use of octreotide is 
controversial [3,7,80]. The insertion of a transjugular intrahe-
patic portosystemic shunt has been reported as emergency 
salvage therapy when endoscopic techniques fail to control 
variceal bleeding [1,81].
Chronic hepatitis B and C in pregnancy
All pregnant women should be screened for hepatitis B virus 
(HBV) early in pregnancy [1,7,81–83]. According to recent EASL 
recommendations, for a woman of child-bearing age without 
advanced fibrosis and cirrhosis who plans a pregnancy in the 
near future, it may be prudent to delay therapy until the child 
is born [82]. In contrast, for pregnant women with chronic HBV 
infection and advanced fibrosis or cirrhosis, therapy with nu-
cleoside analogs (NAs) is recommended, specifically tenofovir 
disoproxil fumarate (TDF) [82].
Vertical infection of infants born to hepatitis B surface antigen 
(HBsAg)-positive mothers is associated with a higher risk of 
chronic infection, and the main risk factors for vertical trans-
mission are the presence of HBe antigen and the maternal vi-
ral load. Therefore, vaccination and anti-HBs immunoglobulin 
should be administered to all newborns from HBV-positive moth-
ers within 12–24 h after delivery. However, some newborns will 
develop HBV infection despite adequate prophylaxis. The risk of 
immunoprophylaxis failure increases with increased maternal 
viral load [1,3,7,82–84]. Immunoprophylaxis failure occurs al-
most exclusively in HBeAg-positive women with high HBV DNA 
levels (>200 000 IU/mL) and/or HBsAg >4–4.5 log10 IU/mL [82]. 
Therefore, NA therapy is suggested during the third trimes-
ter of pregnancy to prevent vertical HBV transmission [1,82].
Pegylated interferon (PEG-IFN) is contraindicated during preg-
nancy. When treatment is indicated, the literature and recent 
EASL recommendations propose TDF as the first-line NA in 
pregnancy. Safety data is available for 2 other NAs during preg-
nancy – lamivudine and telbivudine [1,3,7,82,85,86] – but TDF 
is the preferable NA because it has a better resistance pro-
file and more extensive safety data in pregnant HBV-positive 
women [82]. In women who do not need long-term therapy, 
NA therapy should be discontinued at 1–3 months postpartum, 
but these women should be monitored up to 6 months post-
partum because of the risk of HBV flare-up upon withdrawal 
of antiviral therapy [1,84]. The safety of continuing treatment 
during breast-feeding is uncertain [1,7,82].
The prevalence of anti-hepatitis C virus (HCV) positivity among 
pregnant women in Europe is 1.7–2.5% [7,87,88]. Pregnancy 
does not seem to modify the natural course of HCV disease, 
and does not worsen maternal liver disease or other adverse 
complications in the mother and child [7]. Although chron-
ic HCV infection is thought to rarely influence the course of 
pregnancy [7,89,90,91], a meta-analysis by Huang et al. [90] 
found that maternal HCV infection is significantly associat-
ed with an increased risk of preterm birth. Therefore, further 
studies on this topic are needed. Vertical transmission via the 
mother’s HCV RNA is actually low, occurring in approximately 
3–5% of cases [1,3,92].
Autoimmune liver disease during pregnancy
In the setting of autoimmune hepatitis (AIH), the maternal course 
is highly variable and depends on the timing of the pregnancy 
and preconception preparation of the mother. Westbrook et al. 
[93] analyzed 81 pregnancies in 53 women, with 41% of preg-
nancies occurring in the context of cirrhosis. The live birth rate 
(LBR) was 73%. In cases in which the mother had cirrhosis at 
the time of conception, the LBR rate was lower, with higher inci-
dence of admissions to the neonatal intensive care unit. Disease 
activity flared up in 33% of pregnancies [1,93].
Generally, and in accordance with earlier observations, if a 
pregnancy occurs during an acute episode of AIH, the moth-
er’s liver disease may have a fulminant course with a small 
chance of the baby’s survival. On the other hand, for the wom-
en who are in remission from AIH and do not have cirrhosis 
of the liver and PH, the outcome of the pregnancy may be fa-
vorable [1,7,94,95]. If women have poor disease control in 
the year before pregnancy and lack of drug therapy, the risk 
of poor outcome is high. The most common complication of 
AIH during pregnancy is a flare-up of autoimmune disease, 
which happens more frequently after delivery (11–81% of cas-
es) [1,96]. The use of azathioprine during pregnancy and lac-
tation is thought to be safe [1,7,94,95].
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Liver transplantation and pregnancy
Long-term survival following LT is expected in the majority of 
patients. Following LT, fertility is restored in most women with a 
liver transplant, especially after the first year [1]. The first case 
of successful pregnancy in a patient with transplanted liver 
was described by Walcott et al. [1,97] in 1978. Subsequently, 
there were several publications on pregnancy in transplant-
ed liver patients [1,98–100]. The most important issues in this 
context are maternal and graft risk, optimal immunosuppres-
sion, and fetal outcomes [1,98].
According to a recently published study [98], 117 conceptions 
were achieved in 79 women with liver transplant (median pa-
tient age 29 years). Maternal adverse effects were preeclamp-
sia/eclampsia (15%), acute cellular rejection (ACR; 15%), ges-
tational diabetes (7%), graft loss (2%), and bacterial sepsis 
(5%). Remarkably, more cases of ACR were observed in wom-
en who became pregnant within 12 months after LT. The LBR 
was 73%. In addition, the authors reported that 24 (29%) of 
the neonates had low birth weight, and prematurity occurred 
in 26 (31%) cases. They reported that the choice of immuno-
suppressive therapy (cyclosporine vs. tacrolimus) had no signifi-
cant influence on adverse effects and pregnancy outcomes [98]. 
Therefore, according to the literature, the incidence of ACR can 
be reduced by delaying pregnancy for 1 or 2 years following 
LT in order to achieve stable immunosuppressive therapy and 
ensure that the transplanted organ is functioning well [1,98].
LT patients require life-long immunosuppression, and it should 
be continued throughout pregnancy. Drugs that can general-
ly be used safely during pregnancy are steroids, azathioprine, 
and the calcineurin inhibitor (CNI) tacrolimus. On the other 
hand, the use of mycophenolate during pregnancy is not rec-
ommended. Moreover, mycophenolate should be discontinued 
6 months before conception [1]. Thus, pregnant women with LT 
should be closely and regularly monitored by a multidisciplinary 
team consisting of hepatologists, doctors specializing in trans-
plantation medicine, and obstetricians.
Conclusions
Liver disease during pregnancy is a poorly studied topic and 
poses a challenge for both the gynecologist and hepatologist. 
Challenges involve diagnosis and determining the appropriate 
treatment for the safety of both mother and baby. Liver dis-
ease in pregnancy is a complex issue that deserves a multidis-
ciplinary approach. Nearly 3% of pregnancies are complicat-
ed by liver disease, and severe pregnancy-related liver disease 
can have fatal consequences for the both mother and child. 
Diagnostic and therapeutic decisions must consider the impli-
cations for both, and rapid diagnosis is indispensable for severe 
cases because the decision of immediate delivery is important 
for maternal and fetal outcomes [1–3,5]. In pregnant women 
with suspected liver disease, it is essential to distinguish be-
tween the 2 main categories of liver disease: non-pregnancy-
related liver disease and the few diseases that are directly re-
lated to pregnancy. Pregnancy-related liver disease is the most 
frequent cause of liver dysfunction during pregnancy. We also 
need to keep in mind that pregnancy is associated with many 
normal physiological changes that should be considered in the 
diagnosis of liver disease [1–3]. Pregnancy-related liver disor-
ders exhibit trimester-specific characteristics in their occur-
rence, whereas non-pregnancy-related liver diseases can occur 
at any time [3]. The timing of clinical manifestations and liver 
test result abnormalities can be critical for determining the di-
agnosis and treatment strategies [1,3,7]. More research is need-
ed to understand the epidemiology of pregnancy-related liver 
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